AMEX · YCBD

cbdMD, Inc.

$0.54 -$0.04 (-6.65%) 1D After hours

Key Metrics

$5.65M
Market cap
14.26×
P/E · TTM
$532.13K
Revenue · TTM
$396.15K
Net income
EPS · TTM $0.04
Dividend yield
Free cash flow −$2.65M
Beta · 1Y 1.95
EBITDA · TTM $600.55K
Gross margin -48.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 30 high, the share price fell 48%.

    Peak close $1.04 on Jan 30; trough close $0.54 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -48%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 19
    The stock moved +25.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 19
  • Jan 30
    The stock moved +34.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jan 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$5.65M
Enterprise value
Shares outstanding10.5M
52-wk range$0.47 – $2.56
Avg volume · 20D758.4K
Net cash
Book value / share$0.96
IndustryPerfumes, Cosmetics & Other Toilet Preparations
ExchangeAMEX
About cbdMD, Inc.
IPO dateNov 17, 2017
Employees42

cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E14.26
P/S10.61
P/FCF
EV/EBITDA
EV/Sales
Graham №$0.94

Profitability

Gross -48.6%
Operating 74.4%
Net 74.4%
FCF -498.9%
ROE / ROIC 4.3% · —

Financial Health

Current ratio2.82
Quick ratio1.59
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.42M

Cash Flow · TTM

Operating CF −$2.48M
Capex −$174.83K
Free cash flow −$2.65M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-18.8
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$0.94 vs $0.54
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings